Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab

被引：29

作者：

Berek, JS ^{[1
]}

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Ctr Hlth Sci, Los Angeles, CA 90095 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2004年 / 4卷 / 07期

关键词：

CA125; dendritic cell; mAb B43.13; monoclonal antibody; oregovomab; OvaRex; T cell;

D O I：

10.1517/14712598.4.7.1159

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Recent advances in the molecular and cellular biology of malignancy and tumour immunology have stimulated significant progress in the application of immunotherapies as adjuvant treatments in cancer. Oregovomab (OvaRex(R) AltaRex) is a murine monoclonal antibody with high affinity to the ovarian cancer associated antigen CA125. Infusion of low-dose antibody results in formation of circulating immune complexes which can trigger a cellular immune response targeting CA125 and the ovarian cancer. Oregovomab has activity following initial chemotherapy and in recurrent disease settings and is in Phase III trials to establish its efficacy to prolong time to relapse in patients with advanced ovarian cancer and favourable outcomes to their front-line treatment. Additional studies of antigen processing and combination chemo-immunotherapy are ongoing. The treatment shows promise as a potential new addition to the standard care of ovarian cancer.

引用

页码：1159 / 1165

页数：7

共 38 条

[31] Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor [J].

Saltz, LB ;

Meropol, NJ ;

Loehrer, PJ ;

Needle, MN ;

Kopit, J ;

Mayer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1201-1208

[32] Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assay [J].

Schultes, BC ;

Whiteside, TL .

JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 279 (1-2) :1-15

[33]

Schultes BC, 2002, FASEB J, V16, pA334

[34] Immunotherapy of human ovarian carcinoma with OVAREX™ MAb-B43.13 in a human-PBL-SCID/BG mouse model [J].

Schultes, BC ;

Zhang, CS ;

Xue, LY ;

Noujaim, AA ;

Madiyalakan, R .

HYBRIDOMA, 1999, 18 (01) :47-55

[35]

SCHULTES BC, 2003, P AM ASSOC CANC RES, V43, P144

[36]

Wagner U, 2001, CLIN CANCER RES, V7, P1154

[37] How can we tell when cancer vaccines vaccinate? [J].

Wolchok, JD ;

Chapman, PB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :586-587

[38] Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines [J].

Yip, YL ;

Ward, RL .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 50 (11) :569-587

← 1 2 3 4 →